feedback

Course Director

Richard S. Finn, MD
Richard S. Finn, MD

David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty

Robin K. (“Katie”) Kelley
Robin K. (“Katie”) Kelley, MD

Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Amit Singal
Amit Singal, MD, MS

UT Southwestern Medical Center
Dallas, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Description

The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials.

Target Audience

This activity has been designed to meet the educational needs of medical and gastrointestinal oncologists and other clinicians involved in the management of patients with hepatocellular carcinoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC
  • Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment
  • Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC
  • Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings
  • Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This educational activity is supported by medical education grants from Exelixis, Inc., Genentech, and Merck & Co., Inc.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard S. Finn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for: AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; C stone; Eisai Inc.; Eli Lilly and Company; F. Hoffmann-La Roche/Genentech, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Faculty
Robin K. (“Katie”) Kelley, MD
Associate Professor of Clinical Medicine
Helen Diller Family Comprehensive Cancer Center
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Robin K. (“Katie”) Kelley, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer; Bristol-Myers Squibb; Exelixis, Inc.; and QED Therapeutics without compensation. Consultant and/or Advisor with consulting fees and/or travel support paid to self from F. Hoffmann-La Roche/Genentech, Inc. and Ipsen Biopharmaceuticals, Inc.
Grant/Research Support from Adaptimmune; Agios, Inc.; AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; EMD Serono, Inc.; Exelixis, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics Inc.; QED Therapeutics; and Taiho oncology, Inc. Research Support paid to institution.
Internal Displacement Monitoring Centre (IDMC) member with service fees paid to self from F. Hoffmann-La Roche/Genentech, Inc.

Amit Singal, MD, MS
Associate Professor of Medicine
Medical Director of the Liver Tumor Program
Clinical Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

Amit Singal, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer Corporation; Bristol-Myers Squibb; Eisai Inc.; Exact Sciences; Exelixis, Inc.; F. Hoffmann-La Roche; Genentech, Inc.; Glycotest; Merck & Co., Inc.; and Wako Diagnostics.
Other Financial or Material Support from Target PharmaSolutions, Inc. for Steering Committee.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Natalie I. Vokes, MD
Pamela Ash, RN, MSN, CBCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@peerview.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.


Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.